Monitoring heart failure patients in real-time at Yale New Haven Health System

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Yale Heart Failure Registry is an electronic health records-based registry designed to monitor heart failure cases in real-time across the Yale New Haven Health System. This registry collects comprehensive data on patients diagnosed with heart failure, including demographics, comorbidities, laboratory results, imaging, medications, and clinical outcomes such as hospital readmissions. By updating daily, the registry aims to identify gaps in guideline-recommended therapies and improve the quality of care for heart failure patients through precision medicine.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Seen within the Yale New Haven Health System
* Diagnosis of heart failure

Exclusion Criteria:

* Age\<18

Where it's running

• Yale New Haven Health System
  New Haven, Connecticut, United States Recruiting

Study contacts

• Principal investigator: Tariq Ahmad, MD MPH — Yale University
• Study coordinator: Tariq Ahmad, MD MPH
• Email: Tariq.ahmad@yale.edu
• Phone: (203) 843-1667

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pulmonary Artery Denervation for a specific type of heart and lung pressure problem

  This study tests whether the Enhancor System can safely and effectively help patients with combined pre- and post-capillary pulmonary hypertension due to left heart disease when added to standard therapy.

  Recruiting at 18 sites Pulnovo Medical, Inc. · Tucson, Arizona and 18 other locations · NCT07214376

• Using Apple Watch data to predict heart failure outcomes

  This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.

  Recruiting University Medical Center Goettingen · Goettigen, Lower Saxony · NCT06819618

• Stepwise withdrawal of ARNI and SGLT2i in HF with normalized ejection fraction

  This trial tests whether gradually stopping ARNI and SGLT2i is safe for people whose heart function has recovered after fixing a reversible heart‑disease cause.

  Recruiting Phase 4 Keimyung University Dongsan Medical Center · Daegu, Daegu and 4 other locations · NCT07631156

• Using omecamtiv mecarbil to treat chronic heart failure with severely reduced ejection fraction

  This study is testing if a new drug called omecamtiv mecarbil can help people with severe chronic heart failure live longer and avoid serious heart problems.

  Recruiting at 205 sites Phase 3 Cytokinetics · Alexander City, Alabama and 212 other locations · NCT06736574

• Identifying heart tissue changes in patients with heart failure

  This study looks at changes in heart tissue of people with heart failure to see if it can help find better treatments for their condition.

  Recruiting at 6 sites Northwestern University · Chicago, Illinois and 5 other locations · NCT06517186

• Observational study of heart failure patients in Vietnam

  This study is looking to gather information about heart failure patients in Vietnam to see how they are doing after leaving the hospital and how different treatments affect their health over time.

  Recruiting University Medical Center Ho Chi Minh City (UMC) · Ho Chi Minh City · NCT06516562

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.